This study is testing a new drug called NVL-655 for patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. These tumors have an ALK rearrangement or mutation, meaning they have a change in a gene called ALK that promotes cancer growth. The study is divided into Phase 1 and Phase 2. Phase 1 checks the safety of NVL-655, while Phase 2 looks at how well it works in treating tumors.

Participants are divided into groups based on their previous treatments and the type of cancer they have. The study looks at how long the treatment is effective and how patients respond to it. To join, patients must be at least 18 years old (12 for specific cases) and have a confirmed ALK-positive cancer. They also need to have good organ function and cannot have other cancer mutations or allergies to the study drug.

• The study involves regular visits to the clinic for treatment and check-ups.
• Participants could receive compensation for their time and travel expenses.
• Potential risks include side effects from the drug or complications from the cancer.